Sini San ameliorates lipid metabolism in hyperprolactinemia rat with liver-depression.

Weidong Xu, Shasha Tian, Guanqun Mao, Yu Li, Hua Qian, Wenhua Tao
Author Information
  1. Weidong Xu: School of Pharmacy, Jiangsu University, Zhenjiang, 212013, China.
  2. Shasha Tian: School of Pharmacy, Jiangsu University, Zhenjiang, 212013, China.
  3. Guanqun Mao: Department of Traditional Chinese Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, 212001, China.
  4. Yu Li: School of Pharmacy, Jiangsu University, Zhenjiang, 212013, China.
  5. Hua Qian: Department of Traditional Chinese Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, 212001, China.
  6. Wenhua Tao: Department of Traditional Chinese Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, 212001, China.

Abstract

Sini San (SNS) is used to treat liver depression and is applied in both food and herbal medicine. Hyperprolactinemia (HPRL) is a common endocrine disorder, and patients with HPRL are usually associated with depressive symptoms. However, whether SNS is effective in treating HPRL combined with liver depression and its underlying mechanisms are unknown. We applied network pharmacology and molecular docking to predict the mechanism of SNS for the treatment of liver-depressed HPRL. Therapeutic effects were validated in animal models and cells. Metabolomics was also used to evaluate the effect of SNS on liver-depressed HPRL. Network pharmacology and molecular docking analysis showed that AKT1, TNF and IL6 were the key targets, and SNS improved depressive behaviors, regulated sex hormone levels, and improved ovarian morphology. Combined network pharmacology and metabolomics analyses showed that SNS could act by regulating lipid metabolism. In addition, SNS significantly reduced the release of prolactin (PRL) in rat pituitary tumor MMQ cells. Overall, SNS can significantly treat HPRL liver depression at both animal and cellular levels, and effectively alleviate the related symptoms by regulating lipid metabolism. AKT1, TNF and IL6 may be key targets.

Keywords

References

  1. J Ethnopharmacol. 2023 Sep 15;313:116468 [PMID: 37044233]
  2. Antioxidants (Basel). 2023 Jul 29;12(8): [PMID: 37627518]
  3. PLoS One. 2015 May 07;10(5):e0126492 [PMID: 25951454]
  4. Transl Psychiatry. 2022 Feb 22;12(1):74 [PMID: 35194021]
  5. Front Nutr. 2022 Nov 10;9:968930 [PMID: 36438735]
  6. Neurochem Res. 2013 Apr;38(4):694-704 [PMID: 23338678]
  7. Fertil Steril. 1990 Apr;53(4):677-81 [PMID: 2108058]
  8. Phytomedicine. 2023 Mar;111:154628 [PMID: 36731299]
  9. Acta Pharmacol Sin. 2010 Dec;31(12):1564-8 [PMID: 21042288]
  10. Front Pharmacol. 2020 Jan 16;10:1543 [PMID: 32009955]
  11. Cell Death Dis. 2019 Apr 18;10(5):335 [PMID: 31000722]
  12. Curr Protoc Bioinformatics. 2016 Jun 20;54:1.30.1-1.30.33 [PMID: 27322403]
  13. Cancers (Basel). 2011 Oct 21;3(4):3921-56 [PMID: 24213118]
  14. Clin Biochem. 2018 Dec;62:2-10 [PMID: 29555319]
  15. Phytomedicine. 2022 Nov;106:154395 [PMID: 36103769]
  16. J Transl Med. 2023 Feb 7;21(1):93 [PMID: 36750892]
  17. Transl Psychiatry. 2016 Apr 19;6:e785 [PMID: 27093067]
  18. Curr Res Food Sci. 2024 Jan 30;8:100692 [PMID: 38352629]
  19. Eur J Neurosci. 2024 Mar;59(6):1177-1193 [PMID: 37539658]
  20. Nucleic Acids Res. 2012 Jan;40(Database issue):D565-70 [PMID: 22123736]
  21. Nat Rev Endocrinol. 2015 May;11(5):265-75 [PMID: 25781857]
  22. PLoS One. 2023 Jul 10;18(7):e0287727 [PMID: 37428803]
  23. J Neuroinflammation. 2023 Sep 7;20(1):204 [PMID: 37679787]
  24. Am J Physiol Regul Integr Comp Physiol. 2013 Oct 1;305(7):R720-6 [PMID: 23948778]
  25. Int J Med Sci. 2023 Feb 13;20(4):463-467 [PMID: 37057215]
  26. Front Pharmacol. 2022 Jul 18;13:906256 [PMID: 35924041]
  27. J Psychiatr Res. 2023 Dec;168:165-175 [PMID: 37913743]
  28. Curr Res Food Sci. 2021 Feb 09;4:45-52 [PMID: 33665618]
  29. J Ethnopharmacol. 2023 Dec 5;317:116817 [PMID: 37343654]
  30. J Endocr Soc. 2017 Oct 16;1(11):1362-1371 [PMID: 29264460]
  31. Biomed Pharmacother. 2022 May;149:112861 [PMID: 35339110]
  32. J Ethnopharmacol. 2023 Aug 10;312:116360 [PMID: 37028613]
  33. Int J Mol Sci. 2024 Feb 06;25(4): [PMID: 38396659]
  34. Front Pharmacol. 2021 Nov 29;12:714163 [PMID: 34912211]
  35. Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Sep;1862(9):823-831 [PMID: 28526351]
  36. Microb Biotechnol. 2021 Mar;14(2):517-534 [PMID: 32954686]
  37. Endocrinology. 2023 Nov 2;164(12): [PMID: 37864848]
  38. J Tradit Chin Med. 2019 Jun;39(3):440-450 [PMID: 32186017]
  39. Genome Res. 2003 Nov;13(11):2498-504 [PMID: 14597658]
  40. Aging (Albany NY). 2021 Aug 23;13(16):20418-20437 [PMID: 34424219]
  41. J Ethnopharmacol. 2017 May 23;204:36-44 [PMID: 28396166]
  42. Nutrients. 2022 May 03;14(9): [PMID: 35565884]
  43. Prog Neuropsychopharmacol Biol Psychiatry. 2024 Apr 20;131:110931 [PMID: 38176531]
  44. Front Endocrinol (Lausanne). 2022 Dec 16;13:1057376 [PMID: 36619541]
  45. Brain Behav Immun. 2015 Feb;44:106-20 [PMID: 25218901]
  46. J Mol Med (Berl). 2024 Jan;102(1):113-128 [PMID: 37993562]
  47. Transl Psychiatry. 2022 Jul 5;12(1):267 [PMID: 35790713]
  48. Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613 [PMID: 30476243]
  49. Nucleic Acids Res. 1999 Jan 1;27(1):29-34 [PMID: 9847135]
  50. Pharm Biol. 2023 Dec;61(1):1414-1430 [PMID: 37688460]
  51. Front Pharmacol. 2023 Oct 30;14:1252146 [PMID: 37964876]
  52. Front Pharmacol. 2023 Nov 01;14:1274121 [PMID: 38026979]
  53. Phytomedicine. 2022 May;99:153969 [PMID: 35183930]
  54. Biomed Pharmacother. 2020 Apr;124:109787 [PMID: 31958763]
  55. Antioxidants (Basel). 2021 Jun 03;10(6): [PMID: 34205196]
  56. J Clin Endocrinol Metab. 2020 Mar 1;105(3): [PMID: 31580439]
  57. Front Pharmacol. 2021 Oct 08;12:711303 [PMID: 34690756]
  58. Chin Herb Med. 2023 Dec 01;16(1):132-142 [PMID: 38375048]
  59. Curr Res Food Sci. 2023 Jun 02;6:100527 [PMID: 37377497]
  60. Front Psychiatry. 2022 Nov 09;13:1063489 [PMID: 36440424]
  61. Nutrients. 2022 Apr 25;14(9): [PMID: 35565761]
  62. Biomed Pharmacother. 2023 Dec;168:115677 [PMID: 37857252]
  63. Front Endocrinol (Lausanne). 2023 Jan 24;14:1027905 [PMID: 36761195]
  64. J Cheminform. 2014 Apr 16;6:13 [PMID: 24735618]
  65. Life (Basel). 2023 Oct 26;13(11): [PMID: 38004264]
  66. J Affect Disord. 2023 Jul 15;333:562-570 [PMID: 37080496]
  67. CNS Neurosci Ther. 2024 Apr;30(4):e14519 [PMID: 37905694]
  68. Biomed Pharmacother. 2024 Apr;173:116361 [PMID: 38428310]
  69. Exp Eye Res. 2023 Oct;235:109612 [PMID: 37580001]
  70. Metabolites. 2021 Dec 06;11(12): [PMID: 34940603]
  71. Pharmacol Biochem Behav. 2024 Jun;239:173775 [PMID: 38657873]
  72. Am J Transl Res. 2016 Jul 15;8(7):3049-55 [PMID: 27508025]
  73. Heliyon. 2024 Feb 10;10(4):e25617 [PMID: 38380023]
  74. Front Pharmacol. 2022 Apr 06;13:848355 [PMID: 35462928]

Word Cloud

Created with Highcharts 10.0.0SNSHPRLpharmacologySiniSanliverdepressionlipidmetabolismusedtreatappliedHyperprolactinemiadepressivesymptomsnetworkmoleculardockingliver-depressedanimalcellsMetabolomicsNetworkshowedAKT1TNFIL6keytargetsimprovedlevelsregulatingsignificantlyPRLratfoodherbalmedicinecommonendocrinedisorderpatientsusuallyassociatedHoweverwhethereffectivetreatingcombinedunderlyingmechanismsunknownpredictmechanismtreatmentTherapeuticeffectsvalidatedmodelsalsoevaluateeffectanalysisbehaviorsregulatedsexhormoneovarianmorphologyCombinedmetabolomicsanalysesactadditionreducedreleaseprolactinpituitarytumorMMQOverallcancellulareffectivelyalleviaterelatedmayameliorateshyperprolactinemialiver-depressionDepression

Similar Articles

Cited By

No available data.